Compare BBSI & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | GYRE |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.9M | 750.7M |
| IPO Year | 1994 | 2004 |
| Metric | BBSI | GYRE |
|---|---|---|
| Price | $31.61 | $7.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $40.75 | $18.67 |
| AVG Volume (30 Days) | ★ 190.0K | 141.6K |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 5.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $920,432,000.00 | $275,000.00 |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $5.34 | $27.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $25.33 | $5.44 |
| 52 Week High | $43.53 | $9.42 |
| Indicator | BBSI | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 49.93 |
| Support Level | $29.99 | $6.55 |
| Resistance Level | $31.99 | $7.34 |
| Average True Range (ATR) | 0.96 | 0.34 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 49.05 | 30.15 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.